Axonia Medical, a Kalamazoo, MI-based early stage company developing an innovative approach to repair and restore damaged peripheral and central nervous systems, has closed on $2.0m in seed financing.
The round was led by Southwest Michigan First Life Science Venture Fund, with participation from Ann Arbor SPARK (read here) and Western Michigan University Research Foundation, Biosciences Research and Commercialization Center.
The company intends to use the funding to accelerate development of its lead product for peripheral nerve injury following traumatic injury and tumor resection.
Led by Co-Founder/President & CEO Harry Ledebur, Axonia Medical is pioneering a proprietary approach to repair and restore damaged peripheral or central nervous systems using tissue-engineered nerve grafts (TENGs). By recapitulating the anatomy of the nervous system, TENGs are expected to bridge lost nervous tissue and jump-start regenerative mechanisms to achieve levels of functional recovery not possible with current technologies.
Nervous system injuries comprise a diverse group of disorders that include peripheral nerve injury (PNI), spinal cord injury (SCI), traumatic brain injury (TBI) and stroke.